Sanofi's SAR402663 Receives Fast-Track Designation
Sanofi's groundbreaking therapy, SAR402663, has been granted fast-track designation by the US Food and Drug Administration (FDA) for the treatment of neovascular age-related macular degeneration (AMD). This designation signifies a significant milestone in the development of a one-time intravitreal gene therapy intended to relieve the treatment burden for those living with this severe eye condition.
This Therapy Offers Hope for Patients
Neovascular AMD, often referred to as "wet" AMD, poses a serious risk of vision loss to more than one million individuals in the US alone. As macular degeneration progresses, patients may experience profound difficulties in everyday activities such as reading and driving. SAR402663 holds the promise of potentially eliminating the need for frequent treatments that are currently necessary, thus improving patient quality of life.
A Closer Look at SAR402663
SAR402663 functions by delivering genetic material that encodes soluble FLT01, which is designed to inhibit vascular endothelial growth factor (VEGF). This inhibition is crucial as it reduces the growth of abnormal blood vessels underneath the retina, helping to prevent further vision deterioration. This innovative gene therapy is currently undergoing evaluation in a clinical study, with the aim of determining its efficacy in treating patients suffering from neovascular AMD.
Understanding Neovascular Age-Related Macular Degeneration
AMD is a complex condition characterized by the degeneration of retinal cells, affecting around 200 million people worldwide. When the neovascular form occurs, it results in the growth of aberrant blood vessels that can lead to significant visual impairment and, in severe cases, blindness. The urgency of addressing this condition is underscored by its impact on global health, as millions are burdened by its effects.
Sanofi’s Commitment to Neurology
Sanofi is dedicated to enhancing the lives of individuals suffering from various serious neuroinflammatory and neurodegenerative diseases. The company is at the forefront of researching innovative therapies that target conditions like Alzheimer's disease, multiple sclerosis, Parkinson's disease, and AMD. As it ventures deeper into neurology and ophthalmology, Sanofi seeks to bridge crucial gaps in available treatment options.
Improving Patient Lives through Research and Development
Sanofi, an R&D-driven, AI-powered biopharmaceutical leader, emphasizes its commitment to enriching lives through science. The company focuses on crafting medicines and vaccines that not only treat but protect millions globally. Sanofi’s innovative pipeline presents hope for numerous patients, as it pursues advancements in various therapeutic areas, including retinal diseases with unmet medical needs.
Contacts for Further Information
Media Relations Contacts:
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Investor Relations Contacts:
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Frequently Asked Questions
What is SAR402663?
SAR402663 is an investigational gene therapy developed by Sanofi aimed at treating neovascular age-related macular degeneration (AMD).
Why was SAR402663 given fast-track designation?
The fast-track designation was granted to expedite its development and approval process due to the serious nature of the disease it addresses.
How does SAR402663 work?
SAR402663 delivers genetic material to inhibit VEGF, thereby preventing abnormal blood vessel growth under the retina and protecting vision.
Who does neovascular AMD affect?
Neovascular AMD affects more than one million people in the US and significantly impairs their quality of life.
What is Sanofi's role in neurology?
Sanofi aims to innovate and improve treatments for various serious neurological diseases through extensive research and development efforts.
